Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.40 and traded as low as $0.0510. Eagle Pharmaceuticals shares last traded at $0.0510, with a volume of 472 shares traded.
Eagle Pharmaceuticals Trading Down 86.2%
The company has a 50-day moving average of $0.56 and a 200-day moving average of $0.40. The company has a market capitalization of $662,337.00, a price-to-earnings ratio of 0.04 and a beta of 0.83.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.
The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
Read More
- Five stocks we like better than Eagle Pharmaceuticals
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
